|
AU763839B2
(en)
|
1998-05-26 |
2003-07-31 |
Warner-Lambert Company |
Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
|
|
NZ510760A
(en)
*
|
1998-10-23 |
2003-08-29 |
F |
Bicyclic nitrogen heterocycles
|
|
KR100537241B1
(ko)
*
|
1999-10-21 |
2005-12-19 |
에프. 호프만-라 로슈 아게 |
P38 단백질 키나제의 억제제로서의 알킬아미노 치환된이중고리 질소 헤테로고리 화합물
|
|
DE60033307T2
(de)
*
|
1999-10-21 |
2007-07-12 |
F. Hoffmann-La Roche Ag |
Heteroalkylamino-substituierte bicyclische stickstoffheterocyclen als p38-proteinkinase-inhibitoren
|
|
CN1425008A
(zh)
|
2000-01-24 |
2003-06-18 |
沃尼尔·朗伯公司 |
3-氨基喹唑啉-2,4-二酮抗菌剂
|
|
US7053070B2
(en)
|
2000-01-25 |
2006-05-30 |
Warner-Lambert Company |
Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
|
|
CZ20022475A3
(cs)
*
|
2000-01-25 |
2003-03-12 |
Warner-Lambert Company |
Pyrido[2,3-d]pyrimidin-2,7-diaminové inhibitory kinázy
|
|
US7235551B2
(en)
*
|
2000-03-02 |
2007-06-26 |
Smithkline Beecham Corporation |
1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
|
|
MY141144A
(en)
*
|
2000-03-02 |
2010-03-15 |
Smithkline Beecham Corp |
1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
|
|
PL358271A1
(pl)
*
|
2000-03-06 |
2004-08-09 |
Warner-Lambert Company |
5-alkilopirydo[2,3-D]pirymidyny jako inhibitory kinazy tyrozyny
|
|
WO2002018380A1
(en)
*
|
2000-08-31 |
2002-03-07 |
F. Hoffmann-La Roche Ag |
7-oxo pyridopyrimidines as inhibitors of a cellular proliferation
|
|
US6506749B2
(en)
|
2000-08-31 |
2003-01-14 |
Syntex (U.S.A.) Llc |
7-oxo-pyridopyrimidines (I)
|
|
ATE521353T1
(de)
|
2000-10-23 |
2011-09-15 |
Glaxosmithkline Llc |
Neues trisubstitutiertes 8h-pyridoä2,3- düpyrimidin-7-onderivat zur behandlung von durch csbp/p38kinase vermittelten krankheiten
|
|
GB0029015D0
(en)
|
2000-11-28 |
2001-01-10 |
Univ London |
Medical device
|
|
DE60209886T2
(de)
|
2001-01-19 |
2006-10-26 |
Smithkline Beecham Corp. |
Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
|
|
DE60206363T2
(de)
|
2001-02-12 |
2006-07-06 |
F. Hoffmann-La Roche Ag |
6-substituierte pyridopyrimidine
|
|
US7105667B2
(en)
|
2001-05-01 |
2006-09-12 |
Bristol-Myers Squibb Co. |
Fused heterocyclic compounds and use thereof
|
|
ATE315038T1
(de)
|
2001-05-30 |
2006-02-15 |
Warner Lambert Co |
Antibakterielle mittel
|
|
ES2251677T3
(es)
*
|
2002-01-22 |
2006-05-01 |
Warner-Lambert Company Llc |
2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas.
|
|
US7176310B1
(en)
|
2002-04-09 |
2007-02-13 |
Ucb Sa |
Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents
|
|
KR20040103972A
(ko)
|
2002-04-19 |
2004-12-09 |
스미스클라인 비참 코포레이션 |
신규 화합물
|
|
US7196090B2
(en)
|
2002-07-25 |
2007-03-27 |
Warner-Lambert Company |
Kinase inhibitors
|
|
CA2492112A1
(en)
|
2002-08-06 |
2004-02-19 |
F. Hoffmann-La Roche Ag |
6-alkoxy-pyrido-pyrimidines as p-38 map kinase inhibitors
|
|
US7084270B2
(en)
*
|
2002-08-14 |
2006-08-01 |
Hoffman-La Roche Inc. |
Pyrimido compounds having antiproliferative activity
|
|
TW200413381A
(en)
*
|
2002-11-04 |
2004-08-01 |
Hoffmann La Roche |
Novel amino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents
|
|
US7112676B2
(en)
*
|
2002-11-04 |
2006-09-26 |
Hoffmann-La Roche Inc. |
Pyrimido compounds having antiproliferative activity
|
|
EP1590341B1
(en)
*
|
2003-01-17 |
2009-06-17 |
Warner-Lambert Company LLC |
2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
|
|
JP2006522756A
(ja)
|
2003-04-10 |
2006-10-05 |
エフ.ホフマン−ラ ロシュ アーゲー |
ピリミド化合物
|
|
DE10325133A1
(de)
*
|
2003-06-04 |
2004-12-23 |
Bayer Cropscience Ag |
Triazolopyrimidine
|
|
MXPA06001098A
(es)
|
2003-07-29 |
2006-04-24 |
Irm Llc |
Compuestos y composiciones utiles como inhibidores de proteina cinasa.
|
|
WO2005047284A1
(en)
|
2003-11-13 |
2005-05-26 |
F. Hoffmann-La Roche Ag |
Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
|
|
EP1763514A2
(en)
*
|
2004-05-18 |
2007-03-21 |
Rigel Pharmaceuticals, Inc. |
Cycloalkyl substituted pyrimidinediamine compounds and their uses
|
|
KR100853974B1
(ko)
*
|
2004-08-31 |
2008-08-25 |
에프. 호프만-라 로슈 아게 |
7-아미노-3-페닐 디히드로피리미도[4,5-d]피리미디논의아미드 유도체, 그의 제조 방법 및 약학제로서의 용도
|
|
BRPI0514738A
(pt)
|
2004-08-31 |
2008-06-24 |
Hoffmann La Roche |
derivados de amida de 3-fenil-diidropirimido[4,5-d]pirimidinonas, sua fabricação e aplicação como agentes farmacêuticos
|
|
AU2005316668B2
(en)
|
2004-12-13 |
2012-09-06 |
Millennium Pharmaceuticals, Inc. |
Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors
|
|
UY29439A1
(es)
|
2005-03-25 |
2006-10-02 |
Glaxo Group Ltd |
Nuevos compuestos
|
|
WO2006110298A2
(en)
|
2005-03-25 |
2006-10-19 |
Glaxo Group Limited |
8-alkyl/aryl-4-aryl-2-n- (alkylamino)-n'-substituted-n'-cyanoguanidino-8h-pyrido[2,3-d]pyrimidin-7-one compounds and use thereof
|
|
EP1865959A2
(en)
|
2005-03-25 |
2007-12-19 |
Glaxo Group Limited |
Process for preparing pyridoý2,3-d¨pyrimidin-7-one and 3,4-dihydropyrimidoý4,5-d¨pyrimidin-2(1h)-one derivatives
|
|
UY29440A1
(es)
|
2005-03-25 |
2006-10-02 |
Glaxo Group Ltd |
Nuevos compuestos
|
|
JP2009525292A
(ja)
|
2006-01-31 |
2009-07-09 |
エフ.ホフマン−ラ ロシュ アーゲー |
7h−ピリド[3,4−d]ピリミジン−8−オン、それらの製造及びプロテインキナーゼ阻害剤としての使用
|
|
ES2608940T3
(es)
*
|
2007-06-15 |
2017-04-17 |
Msd K.K. |
Derivado de bicicloanilina
|
|
ES2475206T3
(es)
|
2008-02-01 |
2014-07-10 |
Takeda Pharmaceutical Company Limited |
Derivados de oxima como inhibidores de HSP90
|
|
CA2745959A1
(en)
*
|
2008-12-12 |
2010-06-17 |
Msd K.K. |
Dihydropyrimidopyrimidine derivatives
|
|
EP2376493B1
(en)
*
|
2008-12-12 |
2016-10-05 |
Msd K.K. |
Dihydropyrimidopyrimidine derivative
|
|
EP2379559B1
(en)
*
|
2009-01-06 |
2017-10-25 |
Dana-Farber Cancer Institute, Inc. |
Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
|
|
EP2401281A4
(en)
*
|
2009-02-25 |
2012-08-15 |
Msd Kk |
PYRIMIDINPYRIMIDOINDAZOLDERIVAT
|
|
SA111320200B1
(ar)
|
2010-02-17 |
2014-02-16 |
ديبيوفارم اس ايه |
مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
|
|
CA2807498C
(en)
*
|
2010-08-05 |
2017-02-07 |
Temple University-Of The Commonwealth System Of Higher Education |
2-substituted-8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitriles and uses thereof
|
|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
|
SMT202400031T1
(it)
|
2011-04-22 |
2024-03-13 |
Signal Pharm Llc |
Diamminocarbossammide e diamminocarbonitrile pirimidine sostituite, loro composizioni e metodi di trattamento con esse
|
|
KR101937514B1
(ko)
|
2011-10-14 |
2019-01-10 |
브리스톨-마이어스 스큅 컴퍼니 |
인자 xia 억제제로서의 치환된 테트라히드로이소퀴놀린 화합물
|
|
EP2766345B1
(en)
|
2011-10-14 |
2016-03-16 |
Bristol-Myers Squibb Company |
Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
|
|
ES2579832T3
(es)
|
2011-10-14 |
2016-08-17 |
Bristol-Myers Squibb Company |
Compuestos de tetrahidroisoquinolina sustituida como inhibidores del factor XIa
|
|
ES2704744T3
(es)
|
2012-06-13 |
2019-03-19 |
Incyte Holdings Corp |
Compuestos tricíclicos sustituidos como inhibidores de FGFR
|
|
SMT202100451T1
(it)
*
|
2012-07-11 |
2021-09-14 |
Blueprint Medicines Corp |
Inibitori del recettore di crescita dei fibroblasti
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
WO2014059214A1
(en)
|
2012-10-12 |
2014-04-17 |
Bristol-Myers Squibb Company |
Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
|
|
EP2906552B1
(en)
|
2012-10-12 |
2017-11-22 |
Bristol-Myers Squibb Company |
Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
|
|
TR201807316T4
(tr)
|
2012-10-12 |
2018-06-21 |
Bristol Myers Squibb Co |
Bir faktör XIa inhibitörünün kristalli formları.
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
MY181020A
(en)
|
2013-03-15 |
2020-12-16 |
Sanofi Sa |
Heteroaryl compounds and uses thereof
|
|
TWI647220B
(zh)
|
2013-03-15 |
2019-01-11 |
美商西建卡爾有限責任公司 |
雜芳基化合物及其用途
|
|
ES2712699T3
(es)
|
2013-03-25 |
2019-05-14 |
Bristol Myers Squibb Co |
Tetrahidroisoquinolinas que contienen azoles sustituidos como inhibidores del factor XIa
|
|
EA035095B1
(ru)
*
|
2013-04-19 |
2020-04-27 |
Инсайт Холдингс Корпорейшн |
Бициклические гетероциклы в качестве ингибиторов fgfr
|
|
EP3019491A4
(en)
|
2013-07-09 |
2016-12-21 |
Dana Farber Cancer Inst Inc |
KINASEHEMMER FOR THE TREATMENT OF DISEASES
|
|
MX378288B
(es)
|
2013-10-18 |
2025-03-10 |
Eisai R&D Man Co Ltd |
Inhibidores de pirimidina del fgfr4.
|
|
CA2928042C
(en)
|
2013-10-25 |
2022-05-10 |
Blueprint Medicines Corporation |
Inhibitors of the fibroblast growth factor receptor
|
|
EP3082819B1
(en)
|
2013-12-20 |
2020-06-17 |
Signal Pharmaceuticals, LLC |
Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
|
|
NO2760821T3
(no)
|
2014-01-31 |
2018-03-10 |
|
|
|
CN116987080A
(zh)
|
2014-01-31 |
2023-11-03 |
百时美施贵宝公司 |
作为因子xia抑制剂的具有杂环p2′基团的大环化合物
|
|
CN103880861B
(zh)
*
|
2014-02-21 |
2016-02-03 |
温州医科大学 |
一种作用于FGF受体的4,6-二甲基-噁唑并[5,4-d]嘧啶-5,7(4H,6H)-二酮衍生物
|
|
MA38393B1
(fr)
|
2014-03-13 |
2018-11-30 |
Sanofi Sa |
Composés hétéroaryle et utilisations associées
|
|
CN107074821B
(zh)
|
2014-09-04 |
2020-05-22 |
百时美施贵宝公司 |
为fxia抑制剂的二酰胺大环化合物
|
|
US9453018B2
(en)
|
2014-10-01 |
2016-09-27 |
Bristol-Myers Squibb Company |
Pyrimidinones as factor XIa inhibitors
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
MX373169B
(es)
|
2015-02-20 |
2020-04-24 |
Incyte Holdings Corp |
Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
|
|
WO2016134294A1
(en)
|
2015-02-20 |
2016-08-25 |
Incyte Corporation |
Bicyclic heterocycles as fgfr4 inhibitors
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
SG10201810057UA
(en)
|
2015-04-14 |
2018-12-28 |
Eisai R&D Man Co Ltd |
Crystalline fgfr4 inhibitor compound and uses thereof
|
|
EP3454898B1
(en)
|
2016-05-10 |
2021-11-10 |
Eisai R&D Management Co., Ltd. |
Drug combinations for reducing cell viability and/or cell proliferation
|
|
CN107459519A
(zh)
*
|
2016-06-06 |
2017-12-12 |
上海艾力斯医药科技有限公司 |
稠合嘧啶哌啶环衍生物及其制备方法和应用
|
|
AU2017291812B2
(en)
|
2016-07-05 |
2023-12-14 |
Dana-Farber Cancer Institute, Inc. |
Bicyclic urea kinase inhibitors and uses thereof
|
|
TWI808958B
(zh)
|
2017-01-25 |
2023-07-21 |
美商特普醫葯公司 |
涉及二芳基巨環化合物之組合療法
|
|
BR112019017741A2
(pt)
|
2017-02-28 |
2020-04-07 |
Dana Farber Cancer Inst Inc |
usos de pirimidopirimidinonas como inibidores de sik
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
MA52493A
(fr)
|
2018-05-04 |
2021-03-10 |
Incyte Corp |
Sels d'un inhibiteur de fgfr
|
|
CR20200590A
(es)
|
2018-05-04 |
2021-04-26 |
Incyte Corp |
Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
|
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
TWI891666B
(zh)
|
2019-10-14 |
2025-08-01 |
美商英塞特公司 |
作為fgfr抑制劑之雙環雜環
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
GB201915828D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
|
BR112022010664A2
(pt)
|
2019-12-04 |
2022-08-16 |
Incyte Corp |
Derivados de um inibidor de fgfr
|
|
EP4069696A1
(en)
|
2019-12-04 |
2022-10-12 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
WO2021146424A1
(en)
|
2020-01-15 |
2021-07-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
JP2023525757A
(ja)
*
|
2020-05-08 |
2023-06-19 |
ジョージアミューン・インコーポレイテッド |
Akt3モジュレーター
|
|
WO2021257857A1
(en)
|
2020-06-19 |
2021-12-23 |
Incyte Corporation |
Naphthyridinone compounds as jak2 v617f inhibitors
|
|
WO2021257863A1
(en)
|
2020-06-19 |
2021-12-23 |
Incyte Corporation |
Pyrrolotriazine compounds as jak2 v617f inhibitors
|
|
US11767323B2
(en)
|
2020-07-02 |
2023-09-26 |
Incyte Corporation |
Tricyclic pyridone compounds as JAK2 V617F inhibitors
|
|
SMT202500271T1
(it)
|
2020-07-02 |
2025-09-12 |
Incyte Corp |
Composti di urea triciclici come inibitori di v617f di jak2
|
|
US11661422B2
(en)
|
2020-08-27 |
2023-05-30 |
Incyte Corporation |
Tricyclic urea compounds as JAK2 V617F inhibitors
|
|
CN116529251A
(zh)
*
|
2020-12-02 |
2023-08-01 |
上海瑛派药业有限公司 |
取代的稠合双环化合物作为激酶抑制剂及其应用
|
|
WO2022140231A1
(en)
|
2020-12-21 |
2022-06-30 |
Incyte Corporation |
Deazaguaine compounds as jak2 v617f inhibitors
|
|
AR125273A1
(es)
|
2021-02-25 |
2023-07-05 |
Incyte Corp |
Lactamas espirocíclicas como inhibidores de jak2 v617f
|
|
TW202304459A
(zh)
|
2021-04-12 |
2023-02-01 |
美商英塞特公司 |
包含fgfr抑制劑及nectin-4靶向劑之組合療法
|
|
EP4352059A1
(en)
|
2021-06-09 |
2024-04-17 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
WO2022261159A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
CN119173514A
(zh)
|
2022-03-17 |
2024-12-20 |
因赛特公司 |
作为jak2 v617f抑制剂的三环脲化合物
|
|
WO2024199388A1
(zh)
*
|
2023-03-29 |
2024-10-03 |
微境生物医药科技(上海)有限公司 |
作为myt1抑制剂的化合物
|
|
WO2026024674A1
(en)
|
2024-07-22 |
2026-01-29 |
Genesis Therapeutics, Inc. |
Methods of treating skp2-associated cancers
|